Heusser C H, Anderson C L, Grey H M
J Exp Med. 1977 May 1;145(5):1316-27. doi: 10.1084/jem.145.5.1316.
To evaluate subclass specificity and aggregate size requirements of IgG receptors on mouse cells, we measured binding of radiolabeled monomeric and BDB-aggregated mouse myeloma proteins fractionated into various sizes by means of gel filtration. Monomers, tetramers, and high molecular weight (approximately 10(7) daltons) aggregates were used. The various cells and cell lines studied could be segregated into three patterns of reactivity: (a) Macrophage and macrophage-like cell lines bound monomer IgG2a preferentially; high molecular weight IgG aggregates bound as follows: IgG1 = IgG2b = IgG2a. (b) Lymphoid lines D2N and S49 showed no capacity to bind monomer IgG2a; high molecular weight aggregates bound as follows: IgG1 = IgG2b less than IgG2a. (c) Other Thy-1-positive lymphoid cell lines (EL4 and L5178) and normal T and B cells showed no capacity to bind monomer IgG; high molecular weight IgG aggregates bound to a lesser extent than to cells of the first two categories in the following manner: IgG1 less than IgG2b greater than or equal to IgG2a. The variable pattern of reactivity of the macrophage-like cell lines with monomer and aggregated IgG suggested that two distinct receptors for IgG were present: one capable of binding IgG2a and another capable of binding all aggregates. Further evidence for this hypothesis was obtained by analysis of the inhibitory capacity of different IgG subclasses on the binding of aggregated IgG and monomer IgG2a to P388 cells. Inhibition of monomer IgG2a binding was effected only by monomer or aggregated IgG2a, whereas inhibition of binding of aggregated IgG1 or IgG2b was noted with aggregates of all three subclasses with some preferential inhibition by monomer IgG2b being observed. Furthermore, monomer IgG2b binding was preferentially inhibitable by monomer IgG2b. It is postulated from these data that two receptor sites are present on this macrophage-like cell line, one reactive with aggregates of all three subclasses as well as monomer IgG2b, and another receptor specific for monomer IgG2a which also binds aggregated IgG2a. Support of this concept was obtained by trypsinization experiments in which the binding of monomer IgG2a was markedly decreased by trypsin treatment of cells, whereas the binding of aggregated IgG2b was unaffected by this treatment.
为了评估小鼠细胞上IgG受体的亚类特异性和聚集物大小要求,我们通过凝胶过滤测量了放射性标记的单体和经双功能双马来酰亚胺(BDB)聚集的、被分离成各种大小的小鼠骨髓瘤蛋白的结合情况。使用了单体、四聚体和高分子量(约10⁷道尔顿)的聚集体。所研究的各种细胞和细胞系可分为三种反应模式:(a)巨噬细胞和巨噬细胞样细胞系优先结合单体IgG2a;高分子量IgG聚集体的结合情况如下:IgG1 = IgG2b = IgG2a。(b)淋巴系D2N和S49没有结合单体IgG2a的能力;高分子量聚集体的结合情况如下:IgG1 = IgG2b < IgG2a。(c)其他Thy-1阳性淋巴细胞系(EL4和L5178)以及正常T细胞和B细胞没有结合单体IgG的能力;高分子量IgG聚集体与前两类细胞相比结合程度较低,情况如下:IgG1 < IgG2b ≥ IgG2a。巨噬细胞样细胞系对单体和聚集IgG的反应模式不同,这表明存在两种不同的IgG受体:一种能够结合IgG2a,另一种能够结合所有聚集体。通过分析不同IgG亚类对聚集IgG和单体IgG2a与P388细胞结合的抑制能力,获得了支持这一假设的进一步证据。单体IgG2a结合的抑制仅由单体或聚集的IgG2a实现,而聚集的IgG1或IgG2b结合的抑制在所有三种亚类的聚集体中都有观察到,其中单体IgG2b有一些优先抑制作用。此外,单体IgG2b的结合优先被单体IgG2b抑制。根据这些数据推测,这种巨噬细胞样细胞系上存在两个受体位点,一个与所有三种亚类的聚集体以及单体IgG2b反应,另一个是对单体IgG2a特异的受体,它也能结合聚集的IgG2a。通过胰蛋白酶消化实验支持了这一概念,在该实验中,用胰蛋白酶处理细胞后,单体IgG2a的结合明显减少,而聚集的IgG2b的结合不受该处理的影响。